Matthew Ryan Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew Ryan Bell has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Elias El Haddad
Drexel University, Tower Health Hospital, Philadelphia, USA
8 shared publications - Michele A. Kutzler
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, PA
6 shared publications - Jennifer Connors
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, USA
5 shared publications Bhavani Taramangalam
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, USA
4 shared publicationsDavid Joyner
Drexel University College of Medicine, Department of Medicine, Philadelphia, USA
4 shared publications- Gina Cusimano
Drexel University College of Medicine, Department of Microbiology and Immunology, Philadelphia, USA
4 shared publications
Latest Publications
- Open Access
Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function
Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4 + T cell function, T follicular helper (T FH ) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC T FH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4 + T cells, diminished T FH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4 + T cell generation and cytokine production, activation-induced marker (AIM) T FH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) T FH cells—an age-related defect linked to impaired GC positioning and diminished B cell help—suggesting that ADA improves humoral quality by correcting GC T FH mislocalization. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight-loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.
Open AccessAdenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function
Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4 + T cell function, T follicular helper (T FH ) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC T FH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4 + T cells, diminished T FH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4 + T cell generation and cytokine production, activation-induced marker (AIM) T FH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) T FH cells—an age-related defect linked to impaired GC positioning and diminished B cell help—suggesting that ADA improves humoral quality by correcting GC T FH mislocalization. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight-loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.
- Open Access
- 22 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1
Author Correction: Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
- 22 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1
Open AccessAuthor Correction: Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
- 10 January 2024
- Published by Drexel University Libraries
Identifying Immune Correlates of Protection Against Clostridioides difficile Infection and the Development of an Optimized C. difficile Toxin DNA Vaccine for the Elderly
Clostridioides difficile is the causative agent of C. difficile infection (CDI) which is an enteric infection that leads to severe diarrhea and intestinal inflammation and is the leading healthcare-associated infection in the United States. Due to the high burden of CDI cases and lack of an FDA-approved vaccine, there is immense interest in uncovering the immune correlates of protection against CDI. Previous research has focused on the immune response to the two major pathogenic factors of C. difficile, toxins A and B. Although this research has shown that high serum antitoxin antibody titers are associated with protection from both symptomatic CDI and recurrent CDI (rCDI), there is limited data on the toxin-neutralizing abilities of these serum titers as well as a lack of understanding on the role of cellular and intestinal antitoxin antibody responses in protecting from symptomatic CDI. By recruiting hospitalized patients who were newly diagnosed with CDI, asymptomatic C. difficile carriers, or non-carriers of C. difficile, we show that, while serum and stool antitoxin titers are significantly elevated in asymptomatic carriers compared to CDI cases, the ability of serum antitoxin titers to neutralize toxins A and B does not differ between asymptomatic carriers and CDI cases. Additionally, while serum antitoxin responses in rCDI cases were significantly lower compared to single-episode CDI cases, toxin neutralization was not significantly altered in rCDI cases. Our data also show that asymptomatic carriers of C. difficile present an altered inflammatory phenotype that suggests an important role in the cellular response in protection from symptomatic CDI. Finally, as CDI is an infection that disproportionately impacts the elderly, studies seeking to improve the vaccination response in an aged murine model for CDI show the ability of a novel adjuvant, ADA-1, to improve the humoral and cellular immune responses to a toxin-based DNA vaccine. Taken together, our studies provide evidence that toxin-neutralizing antibody responses do not correlate with protection from symptomatic CDI, demonstrate the potential importance of the cellular immune response in protection against CDI, and show the ability to develop a novel adjuvanted DNA-based vaccine with enhanced immune responses in the context of advanced age.
- 10 January 2024
- Published by Drexel University Libraries
Identifying Immune Correlates of Protection Against Clostridioides difficile Infection and the Development of an Optimized C. difficile Toxin DNA Vaccine for the Elderly
Clostridioides difficile is the causative agent of C. difficile infection (CDI) which is an enteric infection that leads to severe diarrhea and intestinal inflammation and is the leading healthcare-associated infection in the United States. Due to the high burden of CDI cases and lack of an FDA-approved vaccine, there is immense interest in uncovering the immune correlates of protection against CDI. Previous research has focused on the immune response to the two major pathogenic factors of C. difficile, toxins A and B. Although this research has shown that high serum antitoxin antibody titers are associated with protection from both symptomatic CDI and recurrent CDI (rCDI), there is limited data on the toxin-neutralizing abilities of these serum titers as well as a lack of understanding on the role of cellular and intestinal antitoxin antibody responses in protecting from symptomatic CDI. By recruiting hospitalized patients who were newly diagnosed with CDI, asymptomatic C. difficile carriers, or non-carriers of C. difficile, we show that, while serum and stool antitoxin titers are significantly elevated in asymptomatic carriers compared to CDI cases, the ability of serum antitoxin titers to neutralize toxins A and B does not differ between asymptomatic carriers and CDI cases. Additionally, while serum antitoxin responses in rCDI cases were significantly lower compared to single-episode CDI cases, toxin neutralization was not significantly altered in rCDI cases. Our data also show that asymptomatic carriers of C. difficile present an altered inflammatory phenotype that suggests an important role in the cellular response in protection from symptomatic CDI. Finally, as CDI is an infection that disproportionately impacts the elderly, studies seeking to improve the vaccination response in an aged murine model for CDI show the ability of a novel adjuvant, ADA-1, to improve the humoral and cellular immune responses to a toxin-based DNA vaccine. Taken together, our studies provide evidence that toxin-neutralizing antibody responses do not correlate with protection from symptomatic CDI, demonstrate the potential importance of the cellular immune response in protection against CDI, and show the ability to develop a novel adjuvanted DNA-based vaccine with enhanced immune responses in the context of advanced age.
- Open Access
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- Open Access
- 26 October 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (3) , 2267295
Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity
In the field of immunology, a systems biology approach is crucial to understanding the immune response to infection and vaccination considering the complex interplay between genetic, epigenetic, and environmental factors. Significant progress has been made in understanding the innate immune response, including cell players and critical signaling pathways, but many questions remain unanswered, including how the innate immune response dictates host/pathogen responses and responses to vaccines. To complicate things further, it is becoming increasingly clear that the innate immune response is not a linear pathway but is formed from complex networks and interactions. To further our understanding of the crosstalk and complexities, systems-level analyses and expanded experimental technologies are now needed. In this review, we discuss the most recent immunoprofiling techniques and discuss systems approaches to studying the global innate immune landscape which will inform on the development of personalized medicine and innovative vaccine strategies.
- 26 October 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (3) , 2267295
Open AccessUsing the power of innate immunoprofiling to understand vaccine design, infection, and immunity
In the field of immunology, a systems biology approach is crucial to understanding the immune response to infection and vaccination considering the complex interplay between genetic, epigenetic, and environmental factors. Significant progress has been made in understanding the innate immune response, including cell players and critical signaling pathways, but many questions remain unanswered, including how the innate immune response dictates host/pathogen responses and responses to vaccines. To complicate things further, it is becoming increasingly clear that the innate immune response is not a linear pathway but is formed from complex networks and interactions. To further our understanding of the crosstalk and complexities, systems-level analyses and expanded experimental technologies are now needed. In this review, we discuss the most recent immunoprofiling techniques and discuss systems approaches to studying the global innate immune landscape which will inform on the development of personalized medicine and innovative vaccine strategies.
- Open Access
- 17 February 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-13
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
Herein, we studied the impact of empty LNP (eLNP), component of mRNA-based vaccine, on anti-viral pathways and immune function of cells from young and aged individuals. eLNP induced maturation of monocyte derived dendritic cells (MDDCs). We further show that eLNP upregulated CD40 and induced cytokine production in multiple DC subsets and monocytes. This coincided with phosphorylation of TANK binding kinase 1 (pTBK1) and interferon response factor 7 (pIRF7). In response to eLNP, healthy older adults (>65 yrs) have decreased CD40 expression, and IFN-γ output compared to young adults (<65 yrs). Additionally, cells from older adults have a dysregulated anti-viral signaling response to eLNP stimulation, measured by the defect in type I IFN production, and phagocytosis. Overall, our data show function of eLNP in eliciting DC maturation and innate immune signaling pathways that is impaired in older adults resulting in lower immune responses to SARS-CoV-2 mRNA-based vaccines.
- 17 February 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-13
Open AccessLipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
Herein, we studied the impact of empty LNP (eLNP), component of mRNA-based vaccine, on anti-viral pathways and immune function of cells from young and aged individuals. eLNP induced maturation of monocyte derived dendritic cells (MDDCs). We further show that eLNP upregulated CD40 and induced cytokine production in multiple DC subsets and monocytes. This coincided with phosphorylation of TANK binding kinase 1 (pTBK1) and interferon response factor 7 (pIRF7). In response to eLNP, healthy older adults (>65 yrs) have decreased CD40 expression, and IFN-γ output compared to young adults (<65 yrs). Additionally, cells from older adults have a dysregulated anti-viral signaling response to eLNP stimulation, measured by the defect in type I IFN production, and phagocytosis. Overall, our data show function of eLNP in eliciting DC maturation and innate immune signaling pathways that is impaired in older adults resulting in lower immune responses to SARS-CoV-2 mRNA-based vaccines.
- Open Access
- 7 November 2022
- Published by Springer Nature in Research Square
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
Despite the overwhelming success of mRNA-based vaccine in protecting against SARS-CoV-2 infection and reducing disease severity and hospitalization, little is known about the role lipid nanoparticles (LNP) play in initiating immune response. In this report we studied the adjuvantive impact of empty LNP with no mRNA cargo (eLNP) on anti-viral pathways and immune function of cells from young and aged individuals. We found that eLNP induced maturation of monocyte derived dendritic cells by measuring the expression of CD40, CD80, HLA-DR and production of cytokines including IFN-α,IL-6, IFN-γ, IL-12, and IL-21. Flow cytometry analysis of specific dendritic cell subsets showed that eLNP can induce CD40 expression and cytokine production in cDC1, cDC2 and monocytes. Empty LNP (eLNP) effects on dendritic cells and monocytes coincided with induction pIRF7 and pTBK1, which are both important in mitigating innate immune signaling. Interestingly our data show that in response to eLNP stimulus at 6 and 24 hrs, aged individuals have decreased CD40 expression and reduced IFN- γ output compared to young adults. Furthermore, we show that cDC1, cDC2, and CD14dim CD16+ monocytes from healthy aged individuals have dysregulated anti-viral signaling response to eLNP stimulation as measured by the defect in type I IFN production, phosphorylation of IRF7, TBK-1, and immune function like phagocytosis. These data showed a novel function of eLNP in eliciting DC maturation and innate immune signaling pathways and that some of these functions are impaired in older individuals providing some suggestion of why older individuals (> 65 yrs of age) respond display lower immune responses and adverse events to SARS-CoV-2 mRNA-based vaccines.
- 7 November 2022
- Published by Springer Nature in Research Square
Open AccessLipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
Despite the overwhelming success of mRNA-based vaccine in protecting against SARS-CoV-2 infection and reducing disease severity and hospitalization, little is known about the role lipid nanoparticles (LNP) play in initiating immune response. In this report we studied the adjuvantive impact of empty LNP with no mRNA cargo (eLNP) on anti-viral pathways and immune function of cells from young and aged individuals. We found that eLNP induced maturation of monocyte derived dendritic cells by measuring the expression of CD40, CD80, HLA-DR and production of cytokines including IFN-α,IL-6, IFN-γ, IL-12, and IL-21. Flow cytometry analysis of specific dendritic cell subsets showed that eLNP can induce CD40 expression and cytokine production in cDC1, cDC2 and monocytes. Empty LNP (eLNP) effects on dendritic cells and monocytes coincided with induction pIRF7 and pTBK1, which are both important in mitigating innate immune signaling. Interestingly our data show that in response to eLNP stimulus at 6 and 24 hrs, aged individuals have decreased CD40 expression and reduced IFN- γ output compared to young adults. Furthermore, we show that cDC1, cDC2, and CD14dim CD16+ monocytes from healthy aged individuals have dysregulated anti-viral signaling response to eLNP stimulation as measured by the defect in type I IFN production, phosphorylation of IRF7, TBK-1, and immune function like phagocytosis. These data showed a novel function of eLNP in eliciting DC maturation and innate immune signaling pathways and that some of these functions are impaired in older individuals providing some suggestion of why older individuals (> 65 yrs of age) respond display lower immune responses and adverse events to SARS-CoV-2 mRNA-based vaccines.
- Open Access
- 18 July 2022
- Published by Springer Nature in GeroScience
- Vol. 44 (5) , 2555-2572
Aging alters antiviral signaling pathways resulting in functional impairment in innate immunity in response to pattern recognition receptor agonists
The progressive impairment of immunity to pathogens and vaccines with aging is a significant public health problem as the world population shifts to an increased percentage of older adults (> 65). We have previously demonstrated that cells obtained from older volunteers have delayed and defective induction of type I interferons and T cell and B cell helper cytokines in response to TLR ligands when compared to those from adult subjects. However, the underlying intracellular mechanisms are not well described. Herein, we studied two critical pathways important in the production of type I interferon (IFN), the interferon response factor 7 (pIRF7), and TANK-binding kinase (pTBK-1). We show a decrease in pIRF7 and pTBK-1 in cross-priming dendritic cells (cDC1s), CD4+T cell priming DCs (cDC2s), and CD14dimCD16+vascular patrolling monocytes from older adults (n = 11) following stimulation with pathway-specific agonists in comparison with young individuals (n = 11). The decrease in these key antiviral pathway proteins correlates with decreased phagocytosis, suggesting impaired function in Overall, our findings describe molecular mechanisms which explain the innate functional impairment in older adults and thus could inform us of novel approaches to restore these defects.Graphical abstract
- 18 July 2022
- Published by Springer Nature in GeroScience
- Vol. 44 (5) , 2555-2572
Open AccessAging alters antiviral signaling pathways resulting in functional impairment in innate immunity in response to pattern recognition receptor agonists
The progressive impairment of immunity to pathogens and vaccines with aging is a significant public health problem as the world population shifts to an increased percentage of older adults (> 65). We have previously demonstrated that cells obtained from older volunteers have delayed and defective induction of type I interferons and T cell and B cell helper cytokines in response to TLR ligands when compared to those from adult subjects. However, the underlying intracellular mechanisms are not well described. Herein, we studied two critical pathways important in the production of type I interferon (IFN), the interferon response factor 7 (pIRF7), and TANK-binding kinase (pTBK-1). We show a decrease in pIRF7 and pTBK-1 in cross-priming dendritic cells (cDC1s), CD4+T cell priming DCs (cDC2s), and CD14dimCD16+vascular patrolling monocytes from older adults (n = 11) following stimulation with pathway-specific agonists in comparison with young individuals (n = 11). The decrease in these key antiviral pathway proteins correlates with decreased phagocytosis, suggesting impaired function in Overall, our findings describe molecular mechanisms which explain the innate functional impairment in older adults and thus could inform us of novel approaches to restore these defects.Graphical abstract
- Open Access
- 24 June 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (1) , 118-127
Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have demonstrated strong immunogenicity and protection against severe disease, concerns about the duration and breadth of these responses remain. In this study, we show that codelivery of plasmid-encoded adenosine deaminase-1 (pADA) with SARS-CoV-2 spike glycoprotein DNA enhances immune memory and durability in vivo. Coimmunized mice displayed increased spike-specific IgG of higher affinity and neutralizing capacity as compared with plasmid-encoded spike-only–immunized animals. Importantly, pADA significantly improved the longevity of these enhanced responses in vivo. This coincided with durable increases in frequencies of plasmablasts, receptor-binding domain–specific memory B cells, and SARS-CoV-2–specific T follicular helper cells. Increased spike-specific T cell polyfunctionality was also observed. Notably, animals coimmunized with pADA had significantly reduced viral loads compared with their nonadjuvanted counterparts in a SARS-CoV-2 infection model. These data suggest that pADA enhances immune memory and durability and supports further translational studies.
- 24 June 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (1) , 118-127
Open AccessImproved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have demonstrated strong immunogenicity and protection against severe disease, concerns about the duration and breadth of these responses remain. In this study, we show that codelivery of plasmid-encoded adenosine deaminase-1 (pADA) with SARS-CoV-2 spike glycoprotein DNA enhances immune memory and durability in vivo. Coimmunized mice displayed increased spike-specific IgG of higher affinity and neutralizing capacity as compared with plasmid-encoded spike-only–immunized animals. Importantly, pADA significantly improved the longevity of these enhanced responses in vivo. This coincided with durable increases in frequencies of plasmablasts, receptor-binding domain–specific memory B cells, and SARS-CoV-2–specific T follicular helper cells. Increased spike-specific T cell polyfunctionality was also observed. Notably, animals coimmunized with pADA had significantly reduced viral loads compared with their nonadjuvanted counterparts in a SARS-CoV-2 infection model. These data suggest that pADA enhances immune memory and durability and supports further translational studies.
- 21 February 2022
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 183, 114175
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
- 21 February 2022
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 183, 114175
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly